A detailed history of Nuveen Asset Management, LLC transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Nuveen Asset Management, LLC holds 865,631 shares of NTLA stock, worth $18.2 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
865,631
Previous 383,868 125.5%
Holding current value
$18.2 Million
Previous $10.6 Million 83.45%
% of portfolio
0.01%
Previous 0.0%

Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

BUY
$20.02 - $27.22 $9.64 Million - $13.1 Million
481,763 Added 125.5%
865,631 $19.4 Million
Q1 2024

May 13, 2024

SELL
$23.82 - $32.8 $2.19 Million - $3.01 Million
-91,880 Reduced 19.31%
383,868 $10.6 Million
Q4 2023

Feb 14, 2024

SELL
$23.16 - $32.34 $759,925 - $1.06 Million
-32,812 Reduced 6.45%
475,748 $14.5 Million
Q3 2023

Nov 14, 2023

BUY
$31.62 - $45.78 $231,837 - $335,658
7,332 Added 1.46%
508,560 $16.1 Million
Q2 2023

Aug 14, 2023

SELL
$34.58 - $46.03 $19.3 Million - $25.6 Million
-556,990 Reduced 52.63%
501,228 $20.4 Million
Q1 2023

May 15, 2023

BUY
$33.3 - $44.82 $13.1 Million - $17.7 Million
394,012 Added 59.32%
1,058,218 $39.4 Million
Q4 2022

Feb 14, 2023

BUY
$33.21 - $62.69 $9.07 Million - $17.1 Million
272,982 Added 69.78%
664,206 $23.2 Million
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $1.76 Million - $2.34 Million
-32,690 Reduced 7.71%
391,224 $21.9 Million
Q2 2022

Aug 15, 2022

BUY
$38.49 - $76.21 $3.25 Million - $6.43 Million
84,420 Added 24.87%
423,914 $21.9 Million
Q1 2022

May 16, 2022

SELL
$58.27 - $118.99 $874,865 - $1.79 Million
-15,014 Reduced 4.24%
339,494 $23.8 Million
Q4 2021

Feb 14, 2022

SELL
$100.76 - $138.36 $3.15 Million - $4.33 Million
-31,272 Reduced 8.11%
354,508 $41.9 Million
Q3 2021

Nov 12, 2021

SELL
$132.37 - $176.78 $7.54 Million - $10.1 Million
-56,977 Reduced 12.87%
385,780 $51.8 Million
Q2 2021

Aug 16, 2021

SELL
$60.88 - $161.91 $6.77 Million - $18 Million
-111,200 Reduced 20.07%
442,757 $71.7 Million
Q1 2021

May 17, 2021

BUY
$46.59 - $83.68 $2.08 Million - $3.74 Million
44,722 Added 8.78%
553,957 $44.5 Million
Q4 2020

May 17, 2021

BUY
$18.83 - $63.53 $251,342 - $847,998
13,348 Added 2.69%
509,235 $27.7 Million
Q4 2020

Feb 16, 2021

BUY
$18.83 - $63.53 $690,816 - $2.33 Million
36,687 Added 7.99%
495,887 $27 Million
Q3 2020

Nov 16, 2020

BUY
$17.47 - $24.93 $313,009 - $446,670
17,917 Added 4.06%
459,200 $9.13 Million
Q2 2020

Aug 14, 2020

BUY
$11.14 - $22.87 $1.61 Million - $3.31 Million
144,568 Added 48.72%
441,283 $9.28 Million
Q1 2020

May 14, 2020

SELL
$9.44 - $15.58 $2.86 Million - $4.72 Million
-302,688 Reduced 50.5%
296,715 $3.63 Million
Q4 2019

Feb 14, 2020

BUY
$10.43 - $17.67 $4.7 Million - $7.97 Million
451,102 Added 304.18%
599,403 $8.79 Million
Q3 2019

Nov 14, 2019

BUY
$13.07 - $18.51 $9,358 - $13,253
716 Added 0.49%
148,301 $1.98 Million
Q2 2019

Aug 15, 2019

BUY
$13.88 - $18.41 $2.05 Million - $2.72 Million
147,585 New
147,585 $2.42 Million

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $1.6B
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Nuveen Asset Management, LLC Portfolio

Follow Nuveen Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.